Subtype
Urinary Tract Carcinoma
CI-CAN-00007014Explore in graph →
326 active trials11 approved drugs23 evidence items
- NCIt
- C192669
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007014Explore in graph →
Clinical trials
852 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (127)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00407485 | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2014 | clinicaltrials |
| NCT01490437 | Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma(PECULIAR) | completed | Phase 2 | 42 | Asan Medical CenterOTHER | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00471536 | Pazopanib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 3 | May 30, 2014 | clinicaltrials |
| NCT01304173 | Retrospective Chart Review of Valstar | completed | — | 113 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Feb 19, 2014 | clinicaltrials |
| NCT01939756 | Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms(Baobab) | completed | Phase 1 / Phase 2 | 50 | Savino M. Di StasiOTHER | 1 | Sep 11, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00021099 | Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00005831 | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00322699 | Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 22 | North Florida/South Georgia Veterans Health SystemOTHER | 1 | Oct 26, 2012 | clinicaltrials |
| NCT01149174 | Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer(EMDA/PRE-TUR) | completed | Phase 3 | 352 | University of Rome Tor VergataOTHER | 1 | Oct 4, 2011 | clinicaltrials |
| NCT00330707 | Combined Use of BCG and Interferon Alpha in Bladder Cancer | completed | Phase 2 / Phase 3 | 140 | National University Hospital, SingaporeOTHER | 1 | Mar 4, 2011 | clinicaltrials |
| NCT00661609 | A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer | completed | Phase 2 | 54 | AstraZenecaINDUSTRY | 5 | Jan 12, 2011 | clinicaltrials |
| NCT00782587 | Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer(IPOP) | completed | Phase 1 | 14 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 8, 2010 | clinicaltrials |
| NCT00315237 | Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract | completed | Phase 3 | 364 | Pierre Fabre MedicamentINDUSTRY | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00192049 | A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | May 17, 2007 | clinicaltrials |
| NCT00191711 | Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Oct 20, 2014source: clinicaltrials